Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease

Gajra, Ajeet; Newman, Nancy; Gamble, Gary P.; Abraham, Naif Z.; Kohman, Leslie J.; Graziano, Stephen L.

doi:10.1016/s0169-5002(03)00285-x

Cited by 118 publications

(76 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is consistent with previous studies in surgery (28,29), conventional radiotherapy ( Since we have used gated irradiation with the RTRT system, the dose distribution in the lung may be different from non-gated irradiation where organ motion could blur the absorbed dose. If the irradiation with RTRT system can be performed perfectly as planned, the dose distribution in the lung should be very close to the static irradiation (13).…”

Section: Discussionsupporting

confidence: 91%

Steep Dose–Response Relationship for Stage I Non–Small-Cell Lung Cancer Using Hypofractionated High-Dose Irradiation by Real-Time Tumor-Tracking Radiotherapy

Onimaru¹,

Fujino²,

Yamazaki³

et al. 2008

International Journal of Radiation Oncology*Biology*Physics

137

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Steep Dose–Response Relationship for Stage I Non–Small-Cell Lung Cancer Using Hypofractionated High-Dose Irradiation by Real-Time Tumor-Tracking Radiotherapy

Onimaru¹,

Fujino²,

Yamazaki³

et al. 2008

International Journal of Radiation Oncology*Biology*Physics

137

View full text Add to dashboard Cite

show abstract

“…Factors including smoking history, serum level of carcinoembryonic antigen, and tumor size, as well as lymphatic and venous invasion have been identified as poor prognostic factors for lung adenocarcinoma. [8][9][10][11][12] Recently, a pathological entity called the micropapillary pattern has been reported to have worse outcomes in breast, 13 colon, 14 urinary tract, 15 ovary, 16 salivary gland, 17 and lung 18,19 cancer. The micropapillary pattern in lung adenocarcinoma is characterized by small papillary tufts lying in alveolar spaces or in spaces encased by connective tissues, with the tufts having no fibrovascular core, 18,19 and it has been reported as an important factor for poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma

et al. 2008

View full text Add to dashboard Cite

The micropapillary pattern is characterized by small papillary tufts with no fibrovascular core lying in spaces and has been reported as an aggressive variant of carcinoma in several organs. We investigated the histopathobiological properties of the micropapillary pattern with immunohistochemistry, serial sections, and electron microscopy in lung adenocarcinoma. We further analyzed its clinicopathological character and prognosis. The subjects included 383 adenocarcinoma cases, of which 184 (48%) were micropapillary patternpositive and 199 (52%) were micropapillary pattern-negative. On histology, micropapillary tufts seemed to float in the alveolar space or spaces encased by connective tissues, whereas serial sections revealed that most tufts had continuity with other tufts and even with the main tumor. Positive staining for the adhesion molecules E-cadherin and b-catenin suggested the preservation of tight adhesion, and electron microscopy showed the existence of intercellular junctions. Negative staining for laminin and loss of basement membrane as determined by electron microscopy suggest a loss of cell-matrix contact. Positive staining for Ki-67 indicates that cells constituting micropapillary tufts retained their proliferation potency. There were no CD34-positive cells in micropapillary tufts, and the loss of the vascular core was confirmed. In micropapillary pattern-positive cases, lymphatic invasion was identified significantly more frequently than in micropapillary pattern-negative cases (Po0.001), even at stageIA (without lymph node metastasis, N ¼ 197) (Po0.001). The 5-year and 10-year overall survival rates of the micropapillary pattern-positive stageIA group were 77.6 and 67.6%, respectively, which were significantly less than those of the micropapillary pattern-negative stageIA group (98.1 and 98.1%) (P ¼ 0.001). In conclusion, cells constituting the micropapillary pattern are likely to have acquired anchorage-independent growth and a potential for high malignancy.

show abstract

“…Non-small cell lung cancer (NSCLC) accounts for f85% of all lung cancers and has an overall survival at 5 years of <15% (1). Current treatment options for lung cancer include surgery, chemotherapy, and radiation therapy.…”

Section: Introductionmentioning

confidence: 99%

Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells

Ko¹,

Hong

Wang

et al. 2008

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Gefitinib (Iressa, ZD1839) is a selective epidermal growth factor receptor tyrosine kinase inhibitor that can block growth factor-mediated cell proliferation and extracellular signal-regulated kinases 1/2 (ERK1/2) activation. Highlevel Rad51 expression has been reported in chemoresistant or radioresistant carcinomas. In this study, we examined the role of Rad51 in regulating the response to gefitinib among different human lung cancer cell lines. The H520 line (human squamous cell carcinoma) was less sensitive to gefitinib compared with the H1650 (human adenocarcinoma) or A549 (human bronchioloalveolar carcinoma) lines. In H1650 and A549 cells but not in H520 cells, gefitinib decreased cellular levels of phospho-ERK1/2 and Rad51 protein and message levels. Moreover, gefitinib decreased Rad51 protein levels by enhancing Rad51 protein instability through 26S proteasomemediated degradation. Inhibition of endogenous Rad51 levels by si-Rad51 RNA transfection significantly enhanced gefitinib-induced cytotoxicity. In contrast, transfection with constitutively active MKK1 vector could restore both Rad51 protein levels and cell survival inhibited by gefitinib.

show abstract

Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease

Cited by 118 publications

References 16 publications

Steep Dose–Response Relationship for Stage I Non–Small-Cell Lung Cancer Using Hypofractionated High-Dose Irradiation by Real-Time Tumor-Tracking Radiotherapy

Steep Dose–Response Relationship for Stage I Non–Small-Cell Lung Cancer Using Hypofractionated High-Dose Irradiation by Real-Time Tumor-Tracking Radiotherapy

Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma

Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells

Contact Info

Product

Resources

About